Phase 4 N=29 Lemborexant Shift Work Treatment Study
Shift-Work Related Sleep Disturbance
Primary: Daytime Total Sleep Time in Minutes Per Day Collected From the Consensus Sleep Diary — 362.7; 365.3 Minutes per day — p=0.884
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Effects of Daytime Eszopiclone Administration in Shift Workers
Shift-Work Sleep Disorder
Primary: Nighttime Wakefulness Assessed by Mean Sleep Latency Across 4 Maintenance of Wakefulness Tests — 11.0; 14.75 minutes
Phase 4 N=19 Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
Sleep Disorder, Shift-Work
Primary: Change in Average Total Sleep Time — 1.83; -0.33 hours/sleep opportunity — p=<0.05
N/A N=1,189 Fire Fighter Fatigue Management Program: Operation Healthy Sleep
Shift-Work Sleep Disorder · Insomnia · Restless Leg Syndrome
Primary: Firefighters' Health, as Determined by Number of 'Sick' Days Over 12 Months — 3.1; 3.2; 1.4; 2.6 days/firefighter — p=0.66
N/A N=11 Ramelteon for a Nap Prior to a Night Shift
Healthy
Primary: Sleep Efficiency — 89.1; 83.3 percent
Phase 4 N=383 Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
Excessive Sleepiness
Primary: Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at…
N/A N=10 Circadian Rhythm Disruption Effects on Smoke Inhalation
Inflammation · Sleep Deprivation · Circadian Rhythm Sleep Disorder, Shift Work Type
Primary: Blood Inflammation — 0.69; 0.79; 2.33; 1.63 pg/mL — p=<0.05
N/A N=16 Sleep Length and Circadian Regulation in Humans
Sleep Disorders
Primary: Dim Light Melatonin Onset (Hours) — 1.93; 0.80 hours
N/A N=12 Influence of Nocturnal Light Exposure on the Impairment of Glucose Tolerance Induced by Chronic Sleep Restriction
Glucose Intolerance · Sleep Deprivation · Sleep
Primary: Impairment of Insulin Sensitivity — -0.80; 0.55 (mU/L)^-1 min^-1
Early Phase 1 N=30 Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Renal Disease · Sleep Disorders
Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours
N/A N=12 Sleep Disruption Induced Impairments in Bone Formation
Healthy
Primary: Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP) — 72.1; 67.4 ng/mL — p=0.53
N/A N=704 Oregon Military Employee Sleep and Health Study
Well-Being · Sleep · Health Behavior
Primary: Self-Reported Sleep Duration — 7.43; 7.34 Hours
N/A N=489 Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes
Sleep Disorder · Circadian Dysregulation
Primary: Patient-level Outcome: Patient-Reported Outcomes Measurement Information System - Sleep Disturbance — 63.86; 62.10; 62.81; 62.80 T-score — p=<0.001
N/A N=121 A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes
Mental Disorders
Primary: Impairment (Sheehan Disability Scale) — 14.30; 12.03; 11.76; 6.57 score on a scale — p=0.025
Phase 4 N=27 Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
HIV · AIDS · Sleep Disorders
Primary: Percentage of Patients With Viral Loads < 50 Following the Switch — 20 Participants
N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
N/A N=7 Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults
Insomnia Disorder
Primary: Sleep Efficiency — 95.1 percent
N/A N=118 Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease
Sleep Initiation and Maintenance Disorders
Primary: Total Sleep Time — 393; 420; 398; 409 units on a scale (minutes)
N/A N=38 Pilot Study Comparing the Effectiveness of Two Different Methods of Acoustic Stimulation
Sleep Deprivation · Insufficient Sleep Syndrome · Healthy
Primary: The Effects of the Auditory Stimulation on the Cumulative or Average Slow-wave Activity (SWA) Delivered by the PowerSleep & Northwestern Systems in Adults With Mildly…
N/A N=19 The SleepWell Study - Chronotherapeutic Intervention to Improve Sleep Following ACS
Sleep Disturbance · Insomnia · Acute Coronary Syndrome
Primary: Percentage of Participants Who Complete 100% of the Outcome Assessments at Study Conclusion — 4; 7; 5 Participants
N/A N=92 Improving Sleep Using Mentored Behavioral and Environmental Restructuring
Insomnia
Primary: Sleep Efficiency (SE) — 76.1 percentage of time in bed
N/A N=45 Impact of Sleep Restriction on Performance in Adults
Sleep · Obesity · Sleep Restriction
Primary: Endpoint Fat Volume — 24.0; 24.2 Liter
Phase 3 N=254 Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD
Excessive Sleepiness · Shift Work Sleep Disorder
Primary: Multiple Sleep Latency Test (MSLT) — 3.1; 0.4 Minutes — p=<0.0001
N/A N=44 P20 Extending Sleep to Reverse Metabolic Syndrome
Metabolic Syndrome
Primary: SASI Acceptability Questionnaire Score at Pre-Intervention — 3.91 score on a scale
N/A N=33 Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep
Non-visual Photoreception
Primary: Melatonin Suppression — 71.4; 70.1; 54.3; 32.5 Percentage suppression — p=0.73
N/A N=36 Validation of Safety and Efficacy for Night Shift Therapy
Obstructive Sleep Apnea
Primary: Percentage of Participants Who Completed the Study at 4 Weeks Without Adverse Events — 100 Percentage of participants
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
Early Phase 1 N=100 SleepTrackTXT Feasibility and Pilot Study
Fatigue
Primary: Self-Reported Fatigue at End of Shift Work — 2.17; 1.78 units on a scale — p=0.0830
N/A N=120 Home Sleep and Circadian Phase: Mediators of Diabetes Risk
Sleep Deprivation · Diabetes · Circadian Dysregulation
Primary: Oral Disposition Index — 11.5 None (Index) — p=.13